# BrightInsight Financial Model Regulated digital health platform-as-a-service for biopharma and medtech companies to build, launch, and maintain compliant connected-drug and medical-device software products. - Canonical: https://finamodel.com/startups/brightinsight - Excel download: https://finamodel.com/startup-models/brightinsight.xlsx - Category: Biotech/Pharma - Model type: SaaS ARR / Valuation - Funding round: Series B - Funding: $40M - Founded: 2020 - Geography: HQ Silicon Valley; corporate presence in NJ, UK, Switzerland, Copenhagen; platform available in US & EU (regulated), plus 11 additional countries (privacy). [DECK, slide 2] - Customer: B2B2C ## About the company BrightInsight provides managed, regulated cloud infrastructure for connected drugs, medical devices, software as a medical device, and related analytics. Built on Google Cloud, the platform supports device connectivity, data aggregation, EHR integration, clinical dashboards, patient engagement, APIs, and modular product deployment. Its ISO 13485, HITRUST, GDPR, HIPAA, and FDA-oriented compliance stack is positioned as an alternative to expensive in-house builds. Customers such as AstraZeneca, CSL Behring, Novo Nordisk, and Roche can pay platform access fees, implementation services, and potentially usage-based charges, but the deck gives no pricing or ACV. Novo Nordisk uses BrightInsight for connected insulin-pen and glucose-meter data, while Roche launched a CE-marked dosing calculator on the platform. No revenue, customer-count, or retention metrics are disclosed. The model should separate enterprise deployments, recurring platform revenue, regulated support, cloud costs, expansion, and churn. ## What's included - 5-year monthly revenue build with stage-appropriate growth assumptions - Full P&L, headcount plan, and operating-expense schedule - Cash-flow statement, runway, and burn-rate tracking - Valuation via exit multiple with a DCF cross-check - Returns analysis with MOIC and IRR - Unit economics including CAC, LTV, payback, and cohort retention ## Product & value proposition BrightInsight provides a managed, ISO 13485-certified, HITRUST-certified cloud platform (built on Google Cloud) that biopharma and medtech companies use as the underlying regulated infrastructure for connected drugs, Software as a Medical Device (SaMD), connected devices, and clinical/commercial analytics. Core platform capabilities: - Connectivity and device management for regulated apps, algorithms, devices, and combination products - Data aggregation from multiple sources; EHR integration - Clinical, operational, and patient-engagement analytics dashboards - Pre-built APIs, starter software assets, modular/scalable architecture The pitch's core argument: building in-house costs up to $20M and $10M/year to maintain, takes 2+ years, requires 10+ engineers, and is not a competitive advantage for pharma/medtech. Moat elements: ISO 13485 QMS, HITRUST CSF v9.1, GDPR/HIPAA/HDS compliance, Master File with FDA, EC Certification for SaMD, and the only compliant cloud change-control process with Google Cloud. ## Market No explicit TAM/SAM/SOM slide in deck. Referenced market context (industry figures cited, not BrightInsight estimates): - McKinsey estimate: big data could generate $100B in value across US healthcare system through accelerated clinical trials and R&D optimization. - Improving medication adherence by 10% could generate an extra $124B in annual pharma revenues (Capgemini cited). - Escalating pricing/reimbursement pressure for therapies >$100K driving real-world data demand. No market sizing (TAM/SAM/SOM) explicitly presented. ## Revenue model Not explicitly stated in deck. Model is B2B enterprise - customers are global biopharma and medtech companies (AstraZeneca, CSL Behring, Novo Nordisk, Roche named). Inferred from "managed service model" framing: - Platform access fees (annual subscription or multi-year contract) per product deployment or per customer - Professional services / implementation fees for onboarding new digital health products onto the platform - Usage-based components possible (data volume, number of countries/instances), given reference to platform costs scaling with volume No pricing tiers, per-seat pricing, or ACV figures disclosed. ## Traction & metrics Named customers (logos shown): AstraZeneca, CSL Behring, Novo Nordisk, Roche. Case study details: - Novo Nordisk: diabetes care partnership using BrightInsight for connected insulin pens + third-party blood glucose meter data integration. - Roche: CE-marked Dosing Calculator (SaMD) - HEMLIBRA emicizumab dosing calculator launched on the platform. - CSL Behring: platform used for data capture and aggregation across therapies for rare/serious disease patients. Financial/operational metrics: None disclosed (no revenue, ARR, growth rate, customer count, or NRR figures). Dashboard UI figures on slide 7 (25:53, 26,596, 2,000, 8,500, 35%) appear to be illustrative demo dashboard data, not BrightInsight's own business metrics. Team: described as "100+ years of combined digital health experience." Google Cloud Partner of the Year for Healthcare: 2018 and 2019. Media coverage: 20+ outlets referenced. ## Competition / moat No explicit competitive landscape slide. Positioning is against the "build your own" alternative (not named SaaS competitors). Moat: - Only regulated platform with compliant cloud change-control via Google Cloud partnership - ISO 13485, HITRUST, FDA Master File, EC Certification - barriers high for competitors to replicate quickly - Spun out of Flex (hardware manufacturing giant) with embedded regulatory/quality DNA - Google Cloud Partner of the Year Healthcare 2018 + 2019 Named investor/backer Flex is also a strategic partner, providing supply-chain / hardware depth. ## Team & funding ask / use of funds Team (slide 21): - Kal Patel, MD - CEO & Co-Founder - Ferry Tamtoro - CTO & Co-Founder - Ben Lee - Data Architecture & Analytics & Co-Founder - Dave Matthews - Chief Commercial Officer - Swati Reichmuth - Operations - Mark Tarby - Regulatory & Quality Management System - Jamie Burgess - Marketing (VP Marketing, contact on closing slide) - Bob Michitarian - Chief Legal Officer - Marcelo Duhalde - Lead, Digital Health Europe - Mia Naik, CPA - Finance Funding history: - Total raised: $65M - Latest round: Series B, $40M, June 2020 - Investors: Eclipse, Insight Partners, New Leaf Venture Partners (NLV), Flex Funding ask: Not explicitly stated (this appears to be an overview/investor deck at time of Series B close, not a live fundraise deck). --- ## Recommended financial model - **Archetype + why:** B2B Enterprise SaaS ARR model. BrightInsight sells multi-year regulated platform contracts to a small number of large biopharma/medtech enterprises. Revenue is recurring (annual contract value), with professional services layered on. The managed-service framing and regulatory compliance lock-in create high retention and long contract durations - classic enterprise SaaS dynamics. A 3-statement model should sit behind it to show burn rate and path to profitability, given the company is pre-profitability (Series B, no margin data). - **Forecast horizon & granularity:** 5-year forecast (2020–2024), monthly for Year 1 then annual; revenue by customer cohort. - **Key drivers & assumptions:** - Number of enterprise customers (logos) - 2020 base: 4 named customers; 8–12 total active contracts at Series B given company was spun out 2017–2018 - Net new logos per year: 4–8 new enterprise wins/year, given long sales cycles in biopharma/medtech (~9–18 months) and small TAM of decision-makers - Average ACV per customer: $500K–$2M/year platform fee based on comp benchmarks for regulated B2B health infrastructure (no deck data) - Professional services / implementation revenue: 20–30% of platform ACV in year of onboarding - Gross margin on platform: 60–70% at scale; lower early due to high Google Cloud infra costs and customer-specific compliance setup - Churn / logo retention: very low (<5% annual logo churn) - switching cost is enormous (regulatory re-validation of entire platform); NRR likely >110% as customers add products/countries - Countries / product expansions per existing customer: 1–2 new products or geographies per customer per year (expansion revenue driver) - Headcount growth: 20–30% YoY consistent with Series B burn; team is ~10 named leaders, total headcount probably 50–100 - OpEx: heavy R&D (platform expansion) and sales/marketing spend; S&M driven by long-cycle enterprise reps - Burn rate: $15–25M/year based on $40M Series B with ~2-year runway - **Scenarios (Base / Bull / Bear - which variables flex):** - Base: 4–6 new enterprise logos/year; ACV $750K; ~60% gross margin; churn <5% - Bull: 8–10 new logos/year; ACV $1.2M driven by larger customers (global rollouts); expansion to 5+ countries per customer faster - Bear: 2–3 new logos/year (long pharma procurement cycles, COVID disruption in 2020); ACV compression if smaller medtech customers enter the mix; gross margin pressure from custom compliance builds - **Required sheets / outputs:** 1. Assumptions - all drivers in one tab 2. Revenue build - logo cohort waterfall (new logos × ACV + expansion + professional services) 3. P&L - ARR/revenue, COGS (infra + managed service headcount), gross profit, S&M, R&D, G&A, EBITDA 4. Headcount plan - by function 5. Cash flow & runway - monthly burn, cash balance, months of runway post-Series B 6. ARR bridge - opening ARR, new logo, expansion, churn, closing ARR 7. KPI dashboard - logo count, ARR, ACV, NRR, gross margin %, burn rate, runway ## Frequently asked questions ### Is the BrightInsight financial model free? Yes. The BrightInsight model is a free Excel download with live formulas. ### Can I change the assumptions? Yes. The workbook is editable and its live formulas recalculate when assumptions change.